Long Grove Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LONG GROVE PHARMS, and when can generic versions of LONG GROVE PHARMS drugs launch?
LONG GROVE PHARMS has ten approved drugs.
There are six US patents protecting LONG GROVE PHARMS drugs.
There are two patent family members on LONG GROVE PHARMS drugs in two countries and eighty supplementary protection certificates in thirteen countries.
Summary for Long Grove Pharms
| International Patents: | 2 |
| US Patents: | 6 |
| Tradenames: | 11 |
| Ingredients: | 10 |
| NDAs: | 10 |
Drugs and US Patents for Long Grove Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long Grove Pharms | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | INJECTABLE;INJECTION | 213543-001 | Jan 19, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Long Grove Pharms | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214628-003 | Oct 6, 2022 | RX | Yes | Yes | 11,413,259 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Long Grove Pharms | CALCITRIOL | calcitriol | INJECTABLE;INJECTION | 078066-002 | Jan 29, 2008 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Long Grove Pharms | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214628-003 | Oct 6, 2022 | RX | Yes | Yes | 11,602,508 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Long Grove Pharms | EDARAVONE | edaravone | SOLUTION;INTRAVENOUS | 218354-001 | May 6, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Long Grove Pharms | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214628-003 | Oct 6, 2022 | RX | Yes | Yes | 10,568,850 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Long Grove Pharms Drugs
Supplementary Protection Certificates for Long Grove Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2673237 | 1990016-6 | Sweden | ⤷ Sign Up | PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; REG. NO/DATE: EU/1/17/1173 20180326 |
| 0290047 | SPC/GB97/078 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522 |
| 1499331 | 13C0055 | France | ⤷ Sign Up | PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220 |
| 2822954 | LUC00083 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/18/1289 20180625 |
| 1087960 | 1191021-3 | Sweden | ⤷ Sign Up | PRODUCT NAME: ERIBULIN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV, I SYNNERHET ERIBULINMESYLAT EU/1/11/678/001-002, 2011-03-17 EG |
| 1856135 | CA 2020 00018 | Denmark | ⤷ Sign Up | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
